Motohiro Yamamori Selected Research

Aftercare (After-Treatment)

1/2014	Genetic polymorphisms in SLC23A2 as predictive biomarkers of severe acute toxicities after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
1/2013	TNF-α -857C>T genotype is predictive of clinical response after treatment with definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
1/2012	VEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
10/2011	Effects of plasma concentrations of 5-fluorouracil on long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
7/2010	TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Motohiro Yamamori Research Topics

Disease

10	Esophageal Squamous Cell Carcinoma 01/2014 - 06/2007
6	Renal Cell Carcinoma (Grawitz Tumor) 01/2021 - 08/2008
5	Colorectal Neoplasms (Colorectal Cancer) 01/2014 - 02/2009
5	Neoplasms (Cancer) 01/2013 - 02/2008
3	Graft vs Host Disease (Graft-Versus-Host Disease) 04/2017 - 08/2011
3	Hypersensitivity (Allergy) 01/2014 - 03/2011
3	Adenocarcinoma 04/2008 - 12/2004
2	Mucositis 04/2017 - 08/2011
2	Inflammation (Inflammations) 01/2016 - 08/2007
2	Neoplasm Metastasis (Metastasis) 01/2013 - 12/2004
2	Esophageal Neoplasms (Esophageal Cancer) 07/2010 - 05/2009
1	Adenocarcinoma of Lung 01/2022
1	Stomach Neoplasms (Stomach Cancer) 11/2021
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2017
1	Anemia 01/2016
1	Stomatitis 07/2012
1	Head and Neck Neoplasms (Head and Neck Cancer) 10/2011
1	Neutropenia 02/2009
1	Anorexia 02/2009
1	Leukopenia 08/2008
1	Cheilitis 08/2008
1	Carcinoma (Carcinomatosis) 02/2008
1	Autoimmune Diseases (Autoimmune Disease) 12/2007

Drug/Important Bio-Agent (IBA)

12	Fluorouracil (Carac)FDA LinkGeneric 01/2014 - 06/2007
8	Cisplatin (Platino)FDA LinkGeneric 01/2014 - 06/2007
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2012 - 12/2004
3	Mitogen-Activated Protein KinasesIBA 01/2022 - 01/2012
3	Troglitazone (Rezulin)FDA Link 01/2022 - 12/2011
3	Antineoplastic Agents (Antineoplastics)IBA 11/2021 - 10/2011
3	Methotrexate (Mexate)FDA LinkGeneric 04/2017 - 08/2011
3	Mycophenolic Acid (Cellcept)FDA LinkGeneric 04/2017 - 08/2011
3	Biomarkers (Surrogate Marker)IBA 01/2014 - 05/2009
2	Telmisartan (Micardis)FDA Link 11/2021 - 01/2021
2	Cyclosporine (Ciclosporin)FDA LinkGeneric 04/2017 - 12/2007
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2014 - 03/2011
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2014 - 03/2011
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2013 - 07/2010
2	PlatinumIBA 10/2011 - 09/2009
2	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 04/2008 - 02/2008
2	Messenger RNA (mRNA)IBA 04/2008 - 12/2004
1	Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA 01/2022
1	TOR Serine-Threonine KinasesIBA 01/2022
1	Tacrolimus (Prograf)FDA LinkGeneric 04/2017
1	Hemoglobins (Hemoglobin)IBA 01/2016
1	C-Reactive ProteinIBA 01/2016
1	Alanine Transaminase (SGPT)IBA 01/2016
1	NitrogenIBA 01/2016
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2016
1	Urea (Carbamide)FDA LinkGeneric 01/2016
1	Cytostatic AgentsIBA 07/2012
1	Zoledronic Acid (Zometa)FDA Link 05/2012
1	Mevalonic Acid (Mevalonate)IBA 05/2012
1	Thyroid Hormone Receptors beta (TR beta)IBA 01/2012
1	LigandsIBA 01/2012
1	p38 Mitogen-Activated Protein KinasesIBA 12/2011
1	Etoposide (VP 16)FDA LinkGeneric 10/2011
1	Procarbazine (Matulane)FDA Link 10/2011
1	Asparaginase (Elspar)FDA Link 10/2011
1	Teniposide (VM 26)FDA Link 10/2011
1	Paclitaxel (Taxol)FDA LinkGeneric 10/2011
1	Docetaxel (Taxotere)FDA Link 10/2011
1	CamptothecinIBA 07/2011
1	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 07/2011
1	Type II DNA Topoisomerases (Topoisomerase II)IBA 07/2011
1	SteroidsIBA 03/2011
1	nedaplatinIBA 09/2009
1	UracilIBA 02/2009
1	Leucovorin (Folinic Acid)FDA Link 02/2009
1	Irinotecan (Camptosar)FDA LinkGeneric 02/2009
1	TegafurIBA 02/2009
1	Alkaline PhosphataseIBA 04/2008
1	Butyric Acid (Butanoic Acid)IBA 04/2008
1	CollagenIBA 02/2008
1	Prednisolone (Predate)FDA LinkGeneric 08/2007

Therapy/Procedure

10	Chemoradiotherapy 01/2014 - 06/2007
5	Drug Therapy (Chemotherapy) 01/2022 - 08/2008
5	Aftercare (After-Treatment) 01/2014 - 07/2010
3	Hematopoietic Stem Cell Transplantation 04/2017 - 08/2011
2	Therapeutics 01/2014 - 03/2011
2	Radiotherapy 05/2012 - 08/2008
1	Organ Transplantation 07/2012
1	Treatment Delay 02/2009